EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease

Ravi Kumar Akula, Haifa El Kilani, Alina Metzen, Judith Röske, Kaixuan Zhang, Matthias Göhl, Nanaji Arisetti, Graham P Marsh iD, Hannah J Maple iD, Mark S Cooper, Burhan Karadogan, Dirk Jochmans iD und 4 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Ravi Kumar Akula und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology, Helmholtz Centre for Infection Research, Inhoffenstr. 7, Braunschweig 38124, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Pyridones, Coronavirus 3C Proteases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nieders?chsisches Ministerium f?r Wissenschaft und Kultur, Schleswig-Holstein, Universit?t zu L?beck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main protease Mpro is a clinically validated target to treat infections by the coronavirus SARS-CoV-2. Among the first reported Mpro inhibitors was the peptidomimetic α-ketoamide 13b, whose cocrystal structure with Mpro paved the way for multiple lead-finding studies. We established structure-activity relationships for the 13b series by modifying residues at the P1', P3, and P4 sites. Guided by cocrystal structures, we reduced the P1' substituent size to better fill the pocket and added a fluorine substituent to the pyridone ring, enabling a new hydrogen bond with Gln189 in P3. Among 22 novel analogues, 6d and 12d inhibited Mpro with IC50s of 110 nM and 40 nM, improving the potency of 13b by up to 9.5-fold. Compound 6d had pronounced antiviral activity with an EC50 of 1.6 μM and was stable in plasma and microsomes. The study illustrates the potential of structure-based design to systematically improve peptidomimetic α-ketoamides.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsPyridonesCoronavirus 3C ProteasesAmidesStructure-Activity RelationshipHumansProtease InhibitorsCOVID-19 Drug Treatment

Substanzen

Antiviral AgentsPyridonesCoronavirus 3C ProteasesAmidesProtease Inhibitors3C-like proteinase, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Chemical Biology, Helmholtz Centre for Infection Research, Inhoffenstr. 7, Braunschweig 38124, Germany.
  • Institute of Molecular Medicine, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany.
  • German Center for Infection Research (DZIF), Hannover-Braunschweig Site, Braunschweig 38124, Germany.
  • Bio-Techne (Tocris), Bristol BS11 9QD, U.K.
  • Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven 3000, Belgium.
  • German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, Lübeck 23562, Germany.

ORCID-Profile: Graham P Marsh, Hannah J Maple, Dirk Jochmans, Katharina Rox, Mark Brönstrup

Förderung

  • Nieders?chsisches Ministerium f?r Wissenschaft und Kultur
  • Schleswig-Holstein
  • Universit?t zu L?beck
  • Deutsches Zentrum f?r Infektionsforschung
  • Possehl Foundation

Zitieren

APA

Akula, R. K., El Kilani, H., Metzen, A., Röske, J., Zhang, K., Göhl, M., Arisetti, N., Marsh, G. P., Maple, H. J., Cooper, M. S., Karadogan, B., Jochmans, D., Neyts, J., Rox, K., Hilgenfeld, R., & Brönstrup, M. (2025). Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02172

Vancouver

Akula RK, El Kilani H, Metzen A, Röske J, Zhang K, Göhl M, et al. Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02172

BibTeX
@article{Akula2025,
  author = {Akula, Ravi Kumar and El Kilani, Haifa and Metzen, Alina and Röske, Judith and Zhang, Kaixuan and Göhl, Matthias and Arisetti, Nanaji and Marsh, Graham P and Maple, Hannah J and Cooper, Mark S and Karadogan, Burhan and Jochmans, Dirk and Neyts, Johan and Rox, Katharina and Hilgenfeld, Rolf and Brönstrup, Mark},
  title = {Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02172}
}
Kostenlos starten →